Seek Labs

Coming – September 16

Cracking The Code On Molecular Medicine

Date and Time

September 16

–

12:00 PM ET / 9:00 AM PT

Details will be shared with confirmed attendees

About this Event

Seek Labs has been built around a fundamental question: can technology be developed to identify disease earlier and attack it more directly?

Their answer is a new therapeutic modality designed to directly target and destroy disease-associated genetic sequences rather than simply treating the symptoms of a disease. Its Sequence Ablation Therapeutics (SAT™) platform uses programmable CRISPR constructs to enter cells, bind to targeted DNA or RNA, and make multiple cuts intended to break apart the disease-causing sequence.

Preclinical studies provide encouraging proof-of-concept for the platform. In an African Swine Fever animal study, Seek Labs reported approximately 60% survival versus an otherwise lethal infection, while a BioSeeker-generated therapeutic for Lumpy Skin Disease produced 92.7% viral knockdown in an initial study.

Seek Labs is now advancing programs including Influenza A, RSV and Ewing sarcoma, supported by government contracts, research collaborations and industry partnerships. Importantly, Seek is not building its future around a single drug candidate. SAT represents a repeatable therapeutic platform capable of generating multiple applications across infectious disease and selected cancers that have historically been difficult to drug.

Register to reserve your space for an executive briefing with Jared Bauer, Founder and CEO of Seek Labs, for a deep dive into their groundbreaking platform and its potential to transform the treatment of a wide range of diseases.

Sign Up Today

SHARE THIS EVENT

This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts and referenced statistics, contained in this presentation, including statements regarding future company strategy, operations, financial position, revenues, projected costs, plans and objectives of management, will be forward-looking statements.

All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.